There were concerns that the drug was overhyped and approved too quickly. Researchers have said that esketamine, a new drug approved for the treatment of severe treatment-resistant depression by the Food and Drug Administration (FDA) of the US, could give new hope to patients who have not found an effective option. The American regulator approved the drug following the recommendation of an expert panel and applied restricted distribution to the drug, including mandating that it only be administered under medical supervision and monitoring. However, there were concerns that the drug was overhyped and approved too quickly. Esketamine is related to ketamine, which is used as an anaesthetic in humans and animals, but also as a narcotic.

Source: Daily Nation March 12, 2019 07:52 UTC